NAT-SUNITINIB CAPSULE

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

SUNITINIB (SUNITINIB MALATE)

Pieejams no:

NATCO PHARMA (CANADA) INC

ATĶ kods:

L01EX01

SNN (starptautisko nepatentēto nosaukumu):

SUNITINIB

Deva:

50MG

Zāļu forma:

CAPSULE

Kompozīcija:

SUNITINIB (SUNITINIB MALATE) 50MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Produktu pārskats:

Active ingredient group (AIG) number: 0151642003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2023-06-30

Produkta apraksts

PRODUCT MONOGRAPH
PR
NAT-SUNITINIB
Sunitinib capsules
Capsules, 50 mg sunitinib (as sunitinib malate), Oral
Tyrosine Kinase Inhibitor, Anti-Tumour Agent
Natco Pharma (Canada) Inc.
2000 Argentia Road, Plaza 1, Suite 200
Mississauga, Ontario
L5N 1P7
Date of Initial Authorization:
June 29, 2023
Submission Control No.: 254828
_NAT-SUNITINIB Product Monograph _
_Page 2 of 69 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
17
DRUG INTERACTIONS
.................................................................................................
32
DOSAGE AND ADMINISTRATION
.............................................................................
33
OVERDOSAGE
................................................................................................................
34
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 34
STORAGE AND STABILITY
.........................................................................................
38
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 39
PART II: SCIENTIFIC
INFORMATION...............................................................................
40
PHARMACEUTICAL INFORMATION
.........................................................................
40
CLINICAL TRIALS
...